Letter to the Editor: 'Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS‑CoV‑2 disease'-prognostic significance of non-thyroidal illness syndrome across the whole spectrum of COVID-19 severity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Thyroid dysfunction in COVID-19.Nature reviews. Endocrinology · 2024
   Review
2. Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients.Journal of endocrinological investigation · 2022
   Article

Corrections and comments

• Commented on by
  Response to Letter to the Editor from Lui et al.: 'Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease': prognostic significance of non-thyroidal illness syndrome in the whole spectrum of COVID-19 severity.2022
• Comment on
  Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease.2022

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as